MX2022005999A - Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. - Google Patents
Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma.Info
- Publication number
- MX2022005999A MX2022005999A MX2022005999A MX2022005999A MX2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A MX 2022005999 A MX2022005999 A MX 2022005999A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- culturing
- same
- protein
- activity
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 8
- 238000012258 culturing Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000013028 medium composition Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 1
- 239000011324 bead Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 239000013636 protein dimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a una composición para la proliferación de linfocitos T, que contiene un dímero de proteína de fusión que comprende una proteína IL-2 o una variante de esta y una proteína CD80 o un fragmento de esta, y a un método para cultivar los linfocitos T mediante el uso de la misma. Los linfocitos T cultivados de acuerdo con la presente invención aumentan la proliferación y la actividad de los linfocitos T incluso sin usar perlas magnéticas unidas a anticuerpos contra CD3/CD28, y proliferan los linfocitos T mediante el cultivo de células mononucleares de sangre periférica del propio paciente y no es probable que causen efectos secundarios en el cuerpo humano, y por lo tanto se usará ampliamente como un nuevo agente terapéutico de linfocitos T. Además, en el caso de los linfocitos T CD8+ cultivados como se describió anteriormente, la actividad de estos aumenta y, por tanto, los linfocitos T CD8+ pueden usarse como un agente terapéutico más efectivo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190149779 | 2019-11-20 | ||
| PCT/KR2020/016379 WO2021101271A1 (ko) | 2019-11-20 | 2020-11-19 | T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005999A true MX2022005999A (es) | 2022-06-17 |
Family
ID=75981075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005999A MX2022005999A (es) | 2019-11-20 | 2020-11-19 | Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230015408A1 (es) |
| EP (1) | EP4063492A4 (es) |
| JP (1) | JP2023503098A (es) |
| KR (1) | KR20210061956A (es) |
| CN (1) | CN114829585A (es) |
| AU (1) | AU2020389422A1 (es) |
| BR (1) | BR112022009521A2 (es) |
| CA (1) | CA3157613A1 (es) |
| IL (1) | IL292934A (es) |
| MX (1) | MX2022005999A (es) |
| TW (1) | TWI812900B (es) |
| WO (1) | WO2021101271A1 (es) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1986000334A1 (fr) * | 1984-06-20 | 1986-01-16 | Takeda Chemical Industries, Ltd. | Nouveau transformant et son utilisation |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| RU2009110156A (ru) * | 2006-08-23 | 2010-09-27 | Байнекс Ко., Лтд. (Kr) | Способ производства активированных лимфоцитов для иммунотерапии |
| RS54233B1 (en) * | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION |
| KR20230133410A (ko) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
| HUE055284T2 (hu) | 2011-02-10 | 2021-11-29 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| HUE040455T2 (hu) * | 2011-06-30 | 2019-03-28 | Genzyme Corp | T-sejt aktiválás inhibitorai |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| CN103667189B (zh) * | 2013-09-24 | 2015-10-28 | 上海宇研生物技术有限公司 | 用于治疗肺癌的cd8毒性t淋巴细胞及其制备方法 |
| MA45488A (fr) * | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| JP6936221B2 (ja) * | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| CA3019577A1 (en) * | 2016-04-01 | 2017-10-05 | Vycellix Inc | Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells |
| SG11201808411RA (en) * | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| CN110114369A (zh) * | 2016-10-17 | 2019-08-09 | 威隆股份公司 | 修饰的抗体恒定区 |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| CN110204619B (zh) * | 2019-06-11 | 2020-06-05 | 南京融捷康生物科技有限公司 | 包含FcγRⅠ的嵌合抗原受体及其应用 |
-
2020
- 2020-11-19 AU AU2020389422A patent/AU2020389422A1/en active Pending
- 2020-11-19 BR BR112022009521A patent/BR112022009521A2/pt unknown
- 2020-11-19 US US17/777,746 patent/US20230015408A1/en active Pending
- 2020-11-19 EP EP20890984.6A patent/EP4063492A4/en active Pending
- 2020-11-19 KR KR1020200155823A patent/KR20210061956A/ko unknown
- 2020-11-19 JP JP2022529599A patent/JP2023503098A/ja active Pending
- 2020-11-19 WO PCT/KR2020/016379 patent/WO2021101271A1/ko active Application Filing
- 2020-11-19 CA CA3157613A patent/CA3157613A1/en active Pending
- 2020-11-19 MX MX2022005999A patent/MX2022005999A/es unknown
- 2020-11-19 IL IL292934A patent/IL292934A/en unknown
- 2020-11-19 CN CN202080087825.5A patent/CN114829585A/zh active Pending
- 2020-11-20 TW TW109140811A patent/TWI812900B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4063492A1 (en) | 2022-09-28 |
| CN114829585A (zh) | 2022-07-29 |
| US20230015408A1 (en) | 2023-01-19 |
| IL292934A (en) | 2022-07-01 |
| CA3157613A1 (en) | 2021-05-27 |
| TWI812900B (zh) | 2023-08-21 |
| WO2021101271A1 (ko) | 2021-05-27 |
| KR20210061956A (ko) | 2021-05-28 |
| JP2023503098A (ja) | 2023-01-26 |
| BR112022009521A2 (pt) | 2022-08-16 |
| TW202134428A (zh) | 2021-09-16 |
| AU2020389422A1 (en) | 2022-06-02 |
| EP4063492A4 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oyer et al. | PD-L1 blockade enhances anti-tumor efficacy of NK cells | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Sivanathan et al. | Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function | |
| Cheng et al. | Natural killer cell lines in tumor immunotherapy | |
| Hsu et al. | Prostaglandin E2 potentiates mesenchymal stem cell–induced IL-10+ IFN-γ+ CD4+ regulatory T cells to control transplant arteriosclerosis | |
| Lim et al. | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo | |
| US20240050478A1 (en) | Method for Culturing Natural Killer Cells Using T Cells | |
| Gao et al. | Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells | |
| McCurdy et al. | Immune reconstitution after T-cell replete HLA-haploidentical transplantation | |
| Khan et al. | Expanded human blood-derived γδT cells display potent antigen-presentation functions | |
| Min et al. | Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy | |
| Moustaki et al. | Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function | |
| US20200199532A1 (en) | Compositions and methods for expanding ex vivo natural killer cells and therapeutic uses thereof | |
| TWI612137B (zh) | 含免疫細胞之組成物的製造方法及癌症治療用組成物 | |
| CN102428173A (zh) | Nk细胞的扩增 | |
| Torelli et al. | A good manufacturing practice method to ex vivo expand natural killer cells for clinical use | |
| DE69635924D1 (de) | Isolierung und züchtung von schwannzellen | |
| Peragine et al. | Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients | |
| Oyer et al. | Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo | |
| Malone et al. | Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer | |
| Ou et al. | Novel biomanufacturing platform for large-scale and high-quality human T cells production | |
| Bagheri et al. | Current progress in cancer immunotherapy based on natural killer cells | |
| Maldonado-Perez et al. | Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma | |
| CN105838674A (zh) | 一种免疫抑制剂诱导调节性cd8+t细胞体外扩增的方法 | |
| MX2022005999A (es) | Composicion de medio para el cultivo de linfocitos t y metodo para el cultivo de linfocitos t mediante el uso de la misma. |